Outcomes in Pediatric Cord Blood Transplant for Malignant and Non-Malignant Disease Webinar

March 20, 2025

We are proud to present two CBA leaders who will provide valuable insights into pediatric congenital disorders and the impact of umbilical cord blood transplant at Texas Children's Hospital.

Cary A. Martinez, MD, will kick off the webinar with a discussion on "Non-Malignant Pediatric Disorders," offering valuable insights into these complex conditions. Following Caridad, John N. Colgan, MD, DCH, will share his expertise on "Cord Blood Transplant (CBT) for Malignant Diseases - Recent Advances."

Webinar Description: 

Cord blood has long been recognized as an established source of allogenic stem cell transplant for adults and children with malignant and non-malignant disorders. This webinar will go through recent retrospective data has demonstrated unique benefits in the malignant cohort, most notably enhanced GVL in the MRD positive group. Additionally, evolving data in the adult space supports the use of intermediate intensity, but still myeloablative, conditioning in a carefully selected group of cord blood recipients who carry with them a high risk of transplant related toxicity due to pre-existing comorbidities. We will then explore recent advances in cord-blood literature to support these two concepts, whilst presenting the results of a prospective clinical trial for UCB transplant in a malignant cohort receiving either a high-dose TBI or a medium-intensity conditioning regimen at Fred Hutchinson Cancer Centre.

In addition, we will be reviewing the most recent umbilical cord blood outcomes in pediatric patients with non-malignant disorders and how a cord blood donor option is so important in the setting of ethnic minorities. Stem cell transplant centers with an increased minority group of patients face challenges on finding the optimal alternative donor option. We will review the Texas Children’s Hospital cord blood experience in patients with non-malignant disorders in the setting of an increased number of ethnic minorities. Lastly, we will present the most recent data of the Primary Immune Deficiency Consortium with the largest cohort of Umbilical Cord Blood Transplants performed for Severe Combined Immunodeficiency Diseases.

Watch the Webinar Recording

Webinar Speakers

Cary A. Martinez, MD
Associate Professor

Chief, Pediatric Bone Marrow Transplant Center for Cell and Gene Therapy
Texas Children's Hospital / Baylor College of Medicine
Houston, TX

Dr. Martinez serves as the Chief of the Bone Marrow and Cellular Therapy Program at Texas Children's Hospital, Baylor College of Medicine. She has been in the field for more than 20 years and is passionate about improving stem cell transplant outcomes for patients with non-malignant disorders. She is an advocate of umbilical cord blood transplantation in pediatric patients with congenital disorders. Recently, she has shown how a cord blood transplant can be the optimal donor in patients with Severe Combined Immune Deficiency (SCID) when no matched sibling donor is available.

John N. Colgan, MD, DCH
Pediatric Bone Marrow Transplant & Immunotherapy Fellow / Acting Instructor

Fred Hutchinson Cancer Center / University of Washington
Seattle, VA

Dr. John Colgan is the pediatric bone marrow transplant and immunotherapy fellow at Fred Hutchinson Cancer Center and an early career researcher specializing in leukemia biology. John has a specific interest in high-risk leukemia, umbilical cord blood transplantation and functional genomics.

Webinar Agenda

Welcome and Introductions

Non-Malignant Pediatric Disorders
Cary A. Martinez, MD, Texas Children's Hospital / Baylor College of Medicine

Cord Blood Transplant (CBT) for Malignant Diseases - Recent Advances
John N. Colgan, MD, DCH, Fred Hutchinson Cancer Center / University of Washington

Question and Answer with the Panel

Adjourn